A unique research and production complex organized on the principle of full integration.

The Company has all the competencies required to develop and manufacture original and generic medicines to treat cancer and other high-profile diseases.

Since 2020, the Company has been based at Technopolis Moscow SEZ.

Company values

High level of social responsibility

Innovative technological solutions


Adherence to high ethical principles

and r&d center


Manufacturing processes use effective, state-of-the-art equipment from leading foreign companies.

To date, 140 units of high-tech machines of world brands have been purchased, which makes it possible to consolidate efforts in the development, manufacture and quality control of medicines of various dosage forms.

Learn more

Manufacturing capacity:


10 million

packs per year of solid dosage forms

6 million

packs per year of sterile dosage forms

100 kg

per year of small-volume manufacture of apis for own manufacturing needs

r&d center

Own R&D Center develops original, generic and hybrid drugs based on small molecules of chemical origin.
We have created a state-of-the-art research and manufacturing platform for the development and manufacture of our own active pharmaceutical ingredients and finished pharmaceutical products based on them.

Learn more

Targeted therapy

According to the World Health Organization, cancer is one of the leading causes of morbidity and mortality worldwide.

Oncological diseases are systemic and affect all human organs and systems in one way or another.



new cases of oncological diseases were registered in russia in 2020

High mortality rates from cancer can be reduced if the following conditions are met:




Targeted therapy – a type of drug therapy used to treat oncological diseases, has a targeted effect on intracellular mechanisms that affect tumor growth.

Targeted treatment compares favorably with classical chemotherapy in that it "forces" the patient's own immune system to selectively attack only cancer cells, causing little or no damage to healthy cells and body tissues.

Development and registration of antitumor drugs is an urgent task both for the healthcare system as a whole and specifically for the Russian full-cycle pharmaceutical company OncoTarget.

Product portfolio

86% of the product portfolio is included in the list of Vital and Essential Drugs.

Select category

Oncology / Oncohematology




Intensive therapy



HIV and infectious diseases

Company plans:

more than 18

molecules to treat oncological diseases will appear in the company's portfolio

more than 16 million

packs of drugs will be produced

approximately 50

medicinal products are planned for release


OncoTarget manufacturing is in full compliance with international pharmacological industry quality standards.

Закупка дантролена
This field is required
This field is required
Entered incorrect e-mail
This field is required
This field is required
Enter the characters, in the picture: *
You entered the wrong security code
By clicking on the button, you consent your personal data being processed and agree to the privacy policy